VRCA Begins COVE-3 Trial
Verrica Pharmaceuticals announces the first US patient dosed in the COVE-3 trial for YCANTH to treat common warts
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.